# The Impact of Hyperphosphatemia on Mineral and Bone Metabolism: Implications for Bone and Vascular Health

## TL;DR

High blood phosphorus levels, especially in kidney disease, harm bones and blood vessels by disrupting key hormones and causing early damage.

## Contribution

Highlights the role of dietary phosphorus sources and molecular mechanisms linking phosphorus overload to bone and vascular disease.

## Key findings

- Hyperphosphatemia disrupts FGF23, PTH, and vitamin D pathways, leading to bone and vascular damage.
- High dietary phosphorus, even with normal kidney function, mimics CKD-related metabolic changes.
- Inorganic phosphate additives increase systemic phosphorus burden more than other sources.

## Abstract

Phosphorus is an essential mineral involved in bone mineralization, energy metabolism, and cellular signaling, whose serum concentration is tightly regulated by an endocrine network including fibroblast growth factor 23 (FGF23), parathyroid hormone (PTH), vitamin D and Klotho. Disruption of this balance, particularly in chronic kidney disease (CKD), leads to hyperphosphatemia, which is strongly associated with bone fragility, vascular calcification, and increased mortality. In CKD, impaired phosphorus homeostasis triggers endocrine dysregulation characterized by elevated PTH and FGF23 levels, Klotho deficiency, and altered vitamin D metabolism, resulting in major skeletal and vascular consequences. Experimental and clinical evidence indicates that phosphorus overload contributes directly to skeletal deterioration and early vascular remodeling, even prior to clinically detectable renal impairment. Moreover, high dietary phosphorus intake under conditions of normal renal function reproduces several molecular and structural alterations typically observed in CKD, supporting a pathogenic role for chronic phosphorus excess. The dietary source of phosphorus has gained increasing relevance, as inorganic phosphate additives exhibit high intestinal bioavailability and impose a greater systemic phosphorus burden. Current management strategies rely on dietary restriction, phosphate binders, modulation of intestinal phosphorus transport and optimization of mineral-regulating hormones, although evidence for improved clinical outcomes remains limited. A deeper understanding of the molecular mechanisms linking phosphorus overload to bone and vascular pathology may facilitate the development of more effective preventive and therapeutic strategies.